The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Pharma 4.0 Market Research Report 2025
Synopsis
Pharma 4.0 is a holistic operating model for pharmaceutical factories and supply chains of the future based on Industry 4.0 capabilities, digital maturity, and data integrity by design.Pharma 4.0 is a framework for adapting digital strategies to the unique contexts of pharmaceutical manufacturing. In practical terms, it means more connectivity, more productivity, simplified compliance, and the marshaling of production information to respond to problems as they emerge.
Global Pharma 4.0 market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Pharma 4.0 market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Pharma 4.0 market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Pfizer Inc
Abbott Laboratories
GE Healthcare
Boston Scientific
Medtronic Plc.
Lonza Group AG
GlaxoSmithKline plc.
Koninklijke Philips N.V.
Glatt GmbH
Vertex
Johnson & Johnson
Goodly Innovations
QbDVision
Electrosan
GoSilico
Smart Factory
Körber AG
Segment by Type
Cloud
On-premise
Segment by Application
Pharmaceutical Industry
IoT Industry
Medical Equipment Industry
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Pharma 4.0 report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Pharma 4.0 is a holistic operating model for pharmaceutical factories and supply chains of the future based on Industry 4.0 capabilities, digital maturity, and data integrity by design.Pharma 4.0 is a framework for adapting digital strategies to the unique contexts of pharmaceutical manufacturing. In practical terms, it means more connectivity, more productivity, simplified compliance, and the marshaling of production information to respond to problems as they emerge.
Global Pharma 4.0 market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Pharma 4.0 market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Pharma 4.0 market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Pfizer Inc
Abbott Laboratories
GE Healthcare
Boston Scientific
Medtronic Plc.
Lonza Group AG
GlaxoSmithKline plc.
Koninklijke Philips N.V.
Glatt GmbH
Vertex
Johnson & Johnson
Goodly Innovations
QbDVision
Electrosan
GoSilico
Smart Factory
Körber AG
Segment by Type
Cloud
On-premise
Segment by Application
Pharmaceutical Industry
IoT Industry
Medical Equipment Industry
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Pharma 4.0 report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Pharma 4.0 Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Cloud
1.2.3 On-premise
1.3 Market by Application
1.3.1 Global Pharma 4.0 Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Pharmaceutical Industry
1.3.3 IoT Industry
1.3.4 Medical Equipment Industry
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Pharma 4.0 Market Perspective (2018-2029)
2.2 Pharma 4.0 Growth Trends by Region
2.2.1 Global Pharma 4.0 Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Pharma 4.0 Historic Market Size by Region (2018-2023)
2.2.3 Pharma 4.0 Forecasted Market Size by Region (2024-2029)
2.3 Pharma 4.0 Market Dynamics
2.3.1 Pharma 4.0 Industry Trends
2.3.2 Pharma 4.0 Market Drivers
2.3.3 Pharma 4.0 Market Challenges
2.3.4 Pharma 4.0 Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Pharma 4.0 Players by Revenue
3.1.1 Global Top Pharma 4.0 Players by Revenue (2018-2023)
3.1.2 Global Pharma 4.0 Revenue Market Share by Players (2018-2023)
3.2 Global Pharma 4.0 Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Pharma 4.0 Revenue
3.4 Global Pharma 4.0 Market Concentration Ratio
3.4.1 Global Pharma 4.0 Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pharma 4.0 Revenue in 2022
3.5 Pharma 4.0 Key Players Head office and Area Served
3.6 Key Players Pharma 4.0 Product Solution and Service
3.7 Date of Enter into Pharma 4.0 Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Pharma 4.0 Breakdown Data by Type
4.1 Global Pharma 4.0 Historic Market Size by Type (2018-2023)
4.2 Global Pharma 4.0 Forecasted Market Size by Type (2024-2029)
5 Pharma 4.0 Breakdown Data by Application
5.1 Global Pharma 4.0 Historic Market Size by Application (2018-2023)
5.2 Global Pharma 4.0 Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Pharma 4.0 Market Size (2018-2029)
6.2 North America Pharma 4.0 Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Pharma 4.0 Market Size by Country (2018-2023)
6.4 North America Pharma 4.0 Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Pharma 4.0 Market Size (2018-2029)
7.2 Europe Pharma 4.0 Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Pharma 4.0 Market Size by Country (2018-2023)
7.4 Europe Pharma 4.0 Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Pharma 4.0 Market Size (2018-2029)
8.2 Asia-Pacific Pharma 4.0 Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Pharma 4.0 Market Size by Region (2018-2023)
8.4 Asia-Pacific Pharma 4.0 Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Pharma 4.0 Market Size (2018-2029)
9.2 Latin America Pharma 4.0 Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Pharma 4.0 Market Size by Country (2018-2023)
9.4 Latin America Pharma 4.0 Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Pharma 4.0 Market Size (2018-2029)
10.2 Middle East & Africa Pharma 4.0 Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Pharma 4.0 Market Size by Country (2018-2023)
10.4 Middle East & Africa Pharma 4.0 Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer Inc
11.1.1 Pfizer Inc Company Detail
11.1.2 Pfizer Inc Business Overview
11.1.3 Pfizer Inc Pharma 4.0 Introduction
11.1.4 Pfizer Inc Revenue in Pharma 4.0 Business (2018-2023)
11.1.5 Pfizer Inc Recent Development
11.2 Abbott Laboratories
11.2.1 Abbott Laboratories Company Detail
11.2.2 Abbott Laboratories Business Overview
11.2.3 Abbott Laboratories Pharma 4.0 Introduction
11.2.4 Abbott Laboratories Revenue in Pharma 4.0 Business (2018-2023)
11.2.5 Abbott Laboratories Recent Development
11.3 GE Healthcare
11.3.1 GE Healthcare Company Detail
11.3.2 GE Healthcare Business Overview
11.3.3 GE Healthcare Pharma 4.0 Introduction
11.3.4 GE Healthcare Revenue in Pharma 4.0 Business (2018-2023)
11.3.5 GE Healthcare Recent Development
11.4 Boston Scientific
11.4.1 Boston Scientific Company Detail
11.4.2 Boston Scientific Business Overview
11.4.3 Boston Scientific Pharma 4.0 Introduction
11.4.4 Boston Scientific Revenue in Pharma 4.0 Business (2018-2023)
11.4.5 Boston Scientific Recent Development
11.5 Medtronic Plc.
11.5.1 Medtronic Plc. Company Detail
11.5.2 Medtronic Plc. Business Overview
11.5.3 Medtronic Plc. Pharma 4.0 Introduction
11.5.4 Medtronic Plc. Revenue in Pharma 4.0 Business (2018-2023)
11.5.5 Medtronic Plc. Recent Development
11.6 Lonza Group AG
11.6.1 Lonza Group AG Company Detail
11.6.2 Lonza Group AG Business Overview
11.6.3 Lonza Group AG Pharma 4.0 Introduction
11.6.4 Lonza Group AG Revenue in Pharma 4.0 Business (2018-2023)
11.6.5 Lonza Group AG Recent Development
11.7 GlaxoSmithKline plc.
11.7.1 GlaxoSmithKline plc. Company Detail
11.7.2 GlaxoSmithKline plc. Business Overview
11.7.3 GlaxoSmithKline plc. Pharma 4.0 Introduction
11.7.4 GlaxoSmithKline plc. Revenue in Pharma 4.0 Business (2018-2023)
11.7.5 GlaxoSmithKline plc. Recent Development
11.8 Koninklijke Philips N.V.
11.8.1 Koninklijke Philips N.V. Company Detail
11.8.2 Koninklijke Philips N.V. Business Overview
11.8.3 Koninklijke Philips N.V. Pharma 4.0 Introduction
11.8.4 Koninklijke Philips N.V. Revenue in Pharma 4.0 Business (2018-2023)
11.8.5 Koninklijke Philips N.V. Recent Development
11.9 Glatt GmbH
11.9.1 Glatt GmbH Company Detail
11.9.2 Glatt GmbH Business Overview
11.9.3 Glatt GmbH Pharma 4.0 Introduction
11.9.4 Glatt GmbH Revenue in Pharma 4.0 Business (2018-2023)
11.9.5 Glatt GmbH Recent Development
11.10 Vertex
11.10.1 Vertex Company Detail
11.10.2 Vertex Business Overview
11.10.3 Vertex Pharma 4.0 Introduction
11.10.4 Vertex Revenue in Pharma 4.0 Business (2018-2023)
11.10.5 Vertex Recent Development
11.11 Johnson & Johnson
11.11.1 Johnson & Johnson Company Detail
11.11.2 Johnson & Johnson Business Overview
11.11.3 Johnson & Johnson Pharma 4.0 Introduction
11.11.4 Johnson & Johnson Revenue in Pharma 4.0 Business (2018-2023)
11.11.5 Johnson & Johnson Recent Development
11.12 Goodly Innovations
11.12.1 Goodly Innovations Company Detail
11.12.2 Goodly Innovations Business Overview
11.12.3 Goodly Innovations Pharma 4.0 Introduction
11.12.4 Goodly Innovations Revenue in Pharma 4.0 Business (2018-2023)
11.12.5 Goodly Innovations Recent Development
11.13 QbDVision
11.13.1 QbDVision Company Detail
11.13.2 QbDVision Business Overview
11.13.3 QbDVision Pharma 4.0 Introduction
11.13.4 QbDVision Revenue in Pharma 4.0 Business (2018-2023)
11.13.5 QbDVision Recent Development
11.14 Electrosan
11.14.1 Electrosan Company Detail
11.14.2 Electrosan Business Overview
11.14.3 Electrosan Pharma 4.0 Introduction
11.14.4 Electrosan Revenue in Pharma 4.0 Business (2018-2023)
11.14.5 Electrosan Recent Development
11.15 GoSilico
11.15.1 GoSilico Company Detail
11.15.2 GoSilico Business Overview
11.15.3 GoSilico Pharma 4.0 Introduction
11.15.4 GoSilico Revenue in Pharma 4.0 Business (2018-2023)
11.15.5 GoSilico Recent Development
11.16 Smart Factory
11.16.1 Smart Factory Company Detail
11.16.2 Smart Factory Business Overview
11.16.3 Smart Factory Pharma 4.0 Introduction
11.16.4 Smart Factory Revenue in Pharma 4.0 Business (2018-2023)
11.16.5 Smart Factory Recent Development
11.17 Körber AG
11.17.1 Körber AG Company Detail
11.17.2 Körber AG Business Overview
11.17.3 Körber AG Pharma 4.0 Introduction
11.17.4 Körber AG Revenue in Pharma 4.0 Business (2018-2023)
11.17.5 Körber AG Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
